BLSM BlossomHill Therapeutics, Inc.

Fundamentals / CIK 0001839970 / USD

BlossomHill Therapeutics, Inc. reported $124.1M in total assets through June 30, 2026 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open BLSM in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

No annual income statement rows are available in SEC EDGAR CompanyFacts for BLSM.

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2025-09-30 2025-06-30
Research & Development $21.93M $21.36M $14.67M $12.53M
Total Operating Expenses $25.48M $24.67M $16.73M $14.10M
Operating Income -$25.48M -$24.67M -$16.73M -$14.10M
Net Income -$24.01M -$23.76M -$15.98M -$13.24M
Basic EPS -$1.29 -$8.75 -$6.54 -$5.51
Diluted EPS -$1.29 -$8.75 -$6.54 -$5.51
Basic Shares Outstanding 18.6M 2.7M 2.4M 2.4M
Diluted Shares Outstanding 18.6M 2.7M 2.4M 2.4M

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

No annual balance sheet rows are available in SEC EDGAR CompanyFacts for BLSM.

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-06-30 2025-12-31
Cash & Cash Equivalents $95.38M $136.7M
Cash & Short-Term Investments $95.38M $136.7M
Total Current Assets $101.0M $138.8M
Property, Plant & Equipment, Net $1.49M $1.73M
Other Non-Current Assets $2.48M $2.50M
Total Non-Current Assets $23.16M $24.14M
Total Assets $124.1M $163.0M
Accounts Payable $3.93M $2.31M
Other Current Liabilities $809K $0
Total Current Liabilities $18.62M $15.48M
Other Non-Current Liabilities $1.25M $0
Total Non-Current Liabilities $23.47M $22.39M
Total Liabilities $42.09M $37.87M
Total Debt (incl. Leases) $1.15M $5.0K
Common Stock $1.0K $1.0K
Retained Earnings -$179.8M -$135.0M
Total Stockholders' Equity -$174.8M -$131.7M
Total Equity -$174.8M -$131.7M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

No annual cash flow statement rows are available in SEC EDGAR CompanyFacts for BLSM.

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2025-09-30 2025-06-30
Net Income -$24.01M -$23.76M -$15.98M -$13.24M

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

No annual ratios & growth rows are available in SEC EDGAR CompanyFacts for BLSM.

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2025-09-30 2025-06-30
Current Ratio -- 5.42x -- --
Quick Ratio -- 5.12x -- --
Source: SEC EDGAR CompanyFacts (CIK 0001839970) · from June 30, 2025 Data through September 30, 2026 · synced Nov 20, 2026, 05:37 UTC · Open in terminal